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ABSTRACT
Human Adenovirus type 5 encodes two short RNA
polymerase III transcripts, the virus-associated (VA)
RNAI and VA RNAII, which can adopt stable hairpin
structures that resemble micro-RNA precursors.
The terminal stems of the VA RNAs are processed
into small RNAs (mivaRNAs) that are incorporated
into RISC. It has been reported that VA RNAI
has two transcription initiation sites, which
produce two VA RNAI species; a major species, VA
RNAI(G), which accounts for 75% of the VA RNAI
pool, and a minor species, VA RNAI(A), which
initiates transcription three nucleotides upstream
compared to VA RNAI(G). We show that this
50-heterogeneity results in a dramatic difference in
RISC assembly. Thus, both VA RNAI(G) and VA
RNAI(A) are processed by Dicer at the same
position in the terminal stem generating the same
30-strand mivaRNA. This mivaRNA is incorporated
into RISC with 200-fold higher efficiency compared
to the 50-strand of mivaRNAI. Of the small number of
50-strands used in RISC assembly only VA RNAI(A)
generated active RISC complexes. We also show
that the 30-strand of mivaRNAI, although being the
preferred substrate for RISC assembly, generates
unstable RISC complexes with a low in vitro
cleavage activity, only around 2% compared to
RISC assembled on the VA RNAI(A) 50-strand.
INTRODUCTION
RNA interference (RNAi) is a diverse, conserved regula-
tory mechanism in eukaryotic cells, which silences the
target gene expression in a homology-dependent manner
(1). It is well documented that RNAi is an antiviral mech-
anism in plants and insects, although it is still unclear
whether RNAi naturally limits viral infections in
vertebrates (2,3). Viruses are masters of using diﬀerent
strategies to subvert cellular defense mechanisms. They
can not only suppress the eﬀects of defensive RNA
silencing, but also evade or exploit RNAi for their own
beneﬁts.
Several recent studies have shown that during a human
adenovirus infection the activity of the two key enzyme
systems involved in RNAi, Dicer and the RNA-induced
silencing complex (RISC) are suppressed (4–7). The virus-
associated RNAs (VA RNAs) function as suppressors of
RNAi by binding Dicer through their terminal stems and
squelching Dicer as competitive substrates (4,6). They
are cleaved by Dicer into functional small RNAs
(mivaRNAs) that are incorporated into RISC (4,5,7,8).
The eﬀect of an adenovirus infection on cellular miRNA
function could be dramatic since the virus produces
large amounts of the mivaRNAs. Thus, at late times of
infection  80% of Ago2-containing RISC is hijacked by
mivaRNAs (8).
Group C adenovirus encodes two VA RNAs, VA
RNAI (major species, 10
8 molecules/cell) and VA
RNAII (minor species, 5 10
6 molecules per cell). Both
VA RNAs are about 160 nucleotides long, GC-rich and
can adopt stable secondary structures that are important
for their function (9). Besides their roles as RNAi
suppressors, VA RNAI plays a crucial role as a suppressor
of the interferon response. Thus, VA RNAI rescues the
translational capacity of adenovirus-infected cells by
blocking the activity of the dsRNA-dependent protein
kinase (PKR), which inhibits translation in virus-infected
cells by phosphorylating the eukaryotic initiation factor 2
(eIF-2) (10).
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III (11,12) from tRNA like promoters, which are charac-
terized by having internal promoter elements (13,14). The
location of the A and the B boxes (Figure 1B) have been
mapped by genetic analysis in Ad2 VA RNAI. VA RNAI
is heterogeneous at both its 50- and 30-ends, because of the
variation in both transcription initiation and transcription
termination (15,16). Adenovirus-infected cells contain
two VA RNAI species, VA RNAI(A) and VA RNAI(G)
(17). VA RNAI(A) initiates transcription 3 nucleotides
upstream of the start site for VA RNAI(G) (Figure 1C).
VA RNAI(G) is the major species and accounts for 75%
of the total pool of VA RNAI. It has been reported that
a two base pair deletion [nucleotide  25 and  26
(Figure 1C)] results in a complete loss of the VA
RNAI(A) species (16).
In our previous work, we observed that the strand bias
of mivaRNA incorporation into RISC varied when we
used diﬀerent viable Ad5 mutant viruses (4,8). A closer
inspection of the DNA sequence surrounding the VA
RNAI gene demonstrated that in the virus expected to
produce both VA RNAI(G) and VA RNAI(A) both
strands of mivaRNAI could guide RISC to cleave a syn-
thetic target RNA, whereas only the 30-strand of
mivaRNAI generated speciﬁc RISC activity in the virus
expected to produce VA RNAI(G) only (i.e. the two base
pair deletion). Based on this ﬁnding, we suspected that the
heterogeneity at 50-end of VA RNAI could contribute to
the variation of VA RNAI derived small RNA-associated
RISC activity. Here, we show that in Ad5 infected cells the
30-strand of VA RNAI is the preferred strand to be incor-
porated into RISC and exceeds the 50-strand in RISC by
>200-fold. However, these RISC complexes are ineﬃcient
in guiding in vitro RISC cleavage of a target RNA,
showing around 2% of the activity of the 50-strand of
VA RNAI(A). Further, we show that the 50-strand of
VA RNAI(A) is incorporated into RISC and generates
active RISC complexes, whereas the 50-strand of VA
RNAI(G), which is ineﬃciently incorporated into RISC
generates inactive RISC complexes. Dicer cleaves VA
RNAI(A) and VA RNAI(G) at the same position in the
terminal stem resulting in the production of a 50-strand
from VA RNAI(A) that is 3 nucleotides longer than the
corresponding strand processed from VA RNAI(G).
MATERIALS AND METHODS
Cell culture and DNA transfection
A 293 and 293-Ago2 cells were grown in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) supplemented with
10% newborn calf serum (NCS), 100U/ml PEST at
37 Ci n5 %C O 2. All cell culture reagents were purchased
from Gibco/BRL. DNA was transfected using the calcium
phosphate co-precipitation technique (18). Plasmid DNA
was prepared using the Maxiprep kit (Qiagen).
Plasmid construction
Plasmid pVA RNAI G63A contains a point mutation at
position 63 in the VA RNAI gene. The plasmid was con-
structed by PCR ampliﬁcation using primer G63A Forw
(50-ATTCGAGCCCCGTATCCGGCC-30) and primer
G63A Rev (50-CCCGGTCGTCCGCCATGATAC-30).
The ﬁrst nucleotide in the forward primer introduces the
Figure 1. Schematic drawing showing the organization of the VA RNA genes on the adenovirus chromosome. (A) A simpliﬁed transcription map of
the Ad5 genome. Arrows denotes the position of viral early (open) and late (thin) transcription units. (B) Expansion of the genome position encoding
the VA RNA genes. (C) Nucleotide sequence at the promoter site of VA RNAI showing the position of the start site for VA RNAI(G) (bold arrow)
and VA RNAI(A) (thin arrow). The sequence of the 50-end of the major VA RNAI(G) start is indicated in bold letters. The nucleotides deleted in
viruses lacking VA RNAI(A) expression are indicated by a delta sign ().
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used to PCR amplify the VA RNAI gene and the entire
pdl309HindB plasmid. The full-length PCR product was
gel puriﬁed and circularized by religation. Plasmids pVA
RNAI(G) and pVA RNAI(A) were created by PCR
ampliﬁcation using diﬀerent forward primers: primer
VAI-G Start (50-CTTGTGGAAAGGACGAAACACCG
GGCACTCTTCCGTGGTCTGG-30) and VAI-A Start
(50-CTTGTGGAAAGGACGAAACACCAGCGGGCA
CTCTTCCGTGGTCTGG-30) in combination with
primer VAI Rev (50-GGTGTTTCGTCCTTTCCACAA
G-30). Both forward primers contain 22 nucleotides from
the U6 promoter sequence. The U6 promoter was PCR
ampliﬁed with primers U6 Forw (50-ACGGTACCAAG
GTCGGGCAGGAAGAGG-30) and U6 Rev (50-CGGC
AAGCTTAAAAGGAGCACTCCCCCGTTGTCTG-30).
The promoter sequence was fused to the VA RNAI A and
G start through the ﬂanking sequence in a ﬁnal PCR
ampliﬁcation step. In all PCR ampliﬁcation steps,
PfuUltra
TM High-Fidelity DNA Polymerase (Stratagene)
was used. Plasmid dl309HindB was constructed by cloning
the HindIII-B restriction fragment from virus dl309 into
the HindIII site in pBR322. The relevant portion of all
plasmids were veriﬁed by DNA sequencing.
Virus infection
All viruses used are derivatives of Ad5 and have
previously been described. Both wt900 (19) and dl703
(20) are variants of Ad5. Mutant dl328 is a derivative of
dl327, which does not express VA RNAII (21). Cells were
infected with adenovirus at a multiplicity of 10 ﬂuores-
cence forming units (FFU) per cell in DMEM containing
2% NCS. After 45min, the medium was replaced with
fresh medium containing 10% NCS. The uninfected
control cells were treated identically except that virus
was omitted. Twenty four hours later, the cells were har-
vested as described below.
Cytoplasmic S15 extract preparation
Cytoplasmic extracts were prepared as previously des-
cribed (4). Brieﬂy, cells were disrupted by 20–30 strokes
in a 23-gauge syringe needle. The nuclei were pelleted, the
supernatant centrifugated at 15000g for 60min, supple-
mented with 5% glycerol, frozen in liquid nitrogen and
stored at  80 C. The protein concentration was typically
6–8mg/ml.
RISC assay
To generate target RNAs for mivaRNAI, the VA RNAI
gene was separated near the apical loop into two halves
and cloned into a pGL4-Luciferase reporter mRNA in the
reverse orientation, generating target regions complemen-
tary to the 50-(nucleotide 10614–10690, 22) and 30-halves
(nucleotide 10684–10779, 22) of VA RNAI. Target RNAs
complementary to miR-18a, miR-93 and miR-106b were
constructed by cloning 28bp annealed complementary
oligonucleotides into the unique XbaI and FseI restriction
cleavage sites in pGL3-control (Promega). The
32P-labeled
target RNAs were incubated with S15 cytoplasmic
extracts or the anti-FLAG M2 agarose beads (Sigma)
containing puriﬁed RISC under the assay conditions
previously described (4,8). Synthetic short RNA strands
corresponding to the predicted mivaRNAI(A) and
mivaRNAI(G) were purchased from Ambion and
annealed to form duplexes. Reaction mixtures were
incubated for 2h at 30 C and RNA isolated and separated
on a denaturing 8% polyacrylamide gel.
Immunopuriﬁcation of RISC
Cytoplasmic cell extracts were prepared by treatment of
cells on ice for 20min with IsoB-NP-40 (10mM Tris–HCl
pH 7.9, 150mM NaCl, 1.5mM MgCl2, 1% NP-40)
followed by a centrifugation at 16000g for 10min at
4 C. The supernatant from one 10cm culture plate was
incubated with 10ml of anti-FLAG M2 agarose beads
(Sigma) with constant rotation for 3h at 4 C. The beads
were washed three times in NET-1 buﬀer (50mM
Tris–HCl pH 7.5, 150mM NaCl, 2.5% Tween 20).
Co-precipitated RNA was extracted using phenol–
chloroform and subsequently precipitated from the
aqueous phase using ethanol.
Primer extension
Five micrograms of total RNA or small RNA were
incubated with 0.5pmol 50-end labeled primer (50-TCCA
CCAGACCACGGAAGAG-30) in 1.3 Superscript
buﬀer (65mM Tris–HCl, pH 8.3, 97.5mM KCl, 3.9mM
MgCl2)a t7 0  C for 10min. Then, the sample was allowed
to cool down slowly to 45 C and 200U Superscript II
reverse transcriptase (Invitrogen) were added. The
primer extension reaction was incubated at 45 C for 1h
in a buﬀer containing 1 Superscript buﬀer (50mM
Tris–HCl, pH 8.3, 75mM KCl, 3mM MgCl2), 10mM
DTT and 500 mM dNTP. The reaction was terminated
by addition of 1ml 5M NaOH followed by an incubation
at 65 C for 20min. The cDNA was precipitated and
analyzed on a denaturing 15% polyacrylamide gel.
Enzymatic assays of small RNAs
To analyze the 50-end modiﬁcation on mivaRNAI, small
RNAs extracted from immuno-puriﬁed RISC complexes
were treated with diﬀerent enzyme combinations in a total
reaction volume of 23ml under the reaction conditions
recommended by the manufacturer. RNAs were treated
with 20U of calf intestine alkaline phosphatase (CIAP,
Fermentas) for 30min at 37 C, 10U of T4 polynucleotide
kinase (PNK, Fermentas) for 20min at 37 C and 1U of
Terminator 50-exonuclease (TE, Epicentre) for 1h at 30 C.
The reactions were stopped by addition of 1ml 0.5M
EDTA, an equal volume of loading buﬀer was added
and the RNAs separated on a polyacrylamide gel as
described below.
Northern blot analysis
Small RNAs were separated on a denaturing 15%
polyacrylamide gel, and either transferred to a Hybond
NX membrane (Amersham), chemically crosslinked and
hybridized as described (23) (Figure 5), or transferred to
a Hybond XL membrane (Amersham), UV-crosslinked
6952 Nucleic Acids Research, 2009,Vol.37, No. 20and hybridized as described (4) (Figure 6). Hybridization
probes were generated by 50-end labeling of DNA
oligonucleotides complementary to the 50-o r3 0-strand





The strand bias of mivaRNAI association with functional
RISC diﬀers in Ad5 mutant virus infections
By analyzing the RISC activity against substrate RNAs
harboring sequences complementary to the 50 or 30 half of
VA RNAI (Figure 2A), it is possible to determine which
strand of mivaRNAI is incorporated into functional RISC
(4). Comparing the results from our previous work
showed an unexpected asymmetry in strand incorporation
when two diﬀerent viable Ad5 mutant viruses were tested
in our standard RISC assay system (4,8). In dl703 mutant
infected cells, both strands of the terminal stem of VA
RNAI were associated with functional RISC (Figure 2B,
lanes 5 and 6). Also, both strands of VA RNAI generated
active RISC in wild type Ad5-infected cells (Figure 2B,
lanes 3 and 4). In contrast, in wt900mutant infected
cells only the 30-strand generated active RISC
(Figure 2B, lanes 7 and 8). DNA sequence analysis of
the VA RNAI gene demonstrated that they were of the
expected wild-type sequence in all three viruses. However,
we noted that the wt900 virus lacks the 2 base pairs
upstream of the transcription initiation start of the VA
RNAI(G) gene (Figure 1C) that previously have been
shown to be required for transcription initiation from
the A start site (16). In Ad5 and the dl703 virus, the
ﬂanking sequences were of wild-type origin and therefore
both VA RNAI(G) and VA RNA(A) would be expected
to be produced (16).
To determine whether these two nucleotides are respon-
sible for the asymmetry observed in RISC activity, we
identiﬁed the status of mivaRNAI strand incorporation
in Ad5 and diﬀerent Ad5 mutant infected cells. The
results are summarized in Table 1 and show that in
viruses expected to produce both VA RNAI(G) and VA
RNAI(A) (i.e. dl703, dl327, dl328 and wild type Ad5) both
the 50 and the 30-strands of the processed VA RNAI were
incorporated into active RISC, whereas only the 30-strand
was incorporated in wt900 infected cells (two nucleotide
deletion). Also, transfection of a plasmid derived from
Ad5 mutant dl309 (2 nucleotide deletion) that contained
a DNA fragment spanning the VA RNAI gene generated
only RISC complexes derived from the 30-strand of VA
RNAI.
50 mivaRNAI associated RISC activity derives from VA
RNAI(A), but not VA RNAI(G)
Based on the results presented in Table 1, we suspected
that the heterogeneity at the 50-end of VA RNAI was
responsible for the diﬀerence in the assembly of active
RISC in Ad5 mutant infected cells. To test this hypothesis,
we constructed plasmids expressing VA RNAI starting
Figure 2. The strand bias of mivaRNAI incorporating into RISC
diﬀers in wild-type Ad5, dl703 and wt900 infections. (A) The schematic
diagram of RISC substrate RNAs. The VA RNAI gene was separated
within the apical loop into two halves and cloned in anti sense orien-
tation into a reporter mRNA. The
32P-labeled target RNAs containing
the sequence complementary to the 50 or 30 halves of VA RNAI were
generated by in vitro transcription. (B) S15 cytoplasmic extracts
prepared from uninfected 293-Ago2 cells (Mock) or cells infected
with wild-type Ad5, dl703 or wt900 were assayed for RISC activity
against the reverse VAI 50 or VAI 30 target RNAs. Arrows indicate
the span of the VA RNAI target regions in respective transcripts. The
positions of cleavage products are indicated by dots. The bands labeled
with ‘asterisks’ indicate the 30-end cleavage products of the substrate
RNAs, which is sometimes seen but usually degraded in S15 extracts.
Table 1. VA RNAI(A) expression status and the strand bias of
mivaRNAI incorporation into RISC
VA RNAI(A) VA RNAI speciﬁc RISC
50 30
dl703 Yes + +
wild-type Ad5 Yes + +
dl327 Yes + +
dl328 Yes + +
wt900 No   +
pdl309HindB No   +
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position [pVA RNAI(G)]. In order to ensure that only one
species of VA RNAI was transcribed in each case, we
placed the expression of VA RNAI under the control of
the constitutively active U6 promoter, which like the native
VA RNAI promoter is transcribed by RNA polymerase
III, but from a promoter that has the regulatory elements
positioned upstream of the transcription initiation site
(24). To further ensure that the native VA RNAI
promoter was not used, we introduced a point mutation
(G63A) in the critical B-box. This mutation has previously
been shown to reduce transcription activity of VA RNAI
to 1% in vitro (25). The transcription initiation start sites
were veriﬁed for both pVA RNAI(A) and pVA RNA(G)
by primer extension (Figure 3B, lanes 2 and 3).
The 293 cells stably expressing a FLAG tagged Ago2
protein [293-Ago2; (8)] were transfected with either pVA
RNAI(A) or pVA RNAI(G). S15 cytoplasmic extracts
were prepared 48h posttransfection and Ago2-containing
complexes immuno-puriﬁed by binding to an anti-FLAG
M2 agarose resin, and the RISC activity assayed using our
standard RISC assay protocol. The results show that both
strands of VA RNAI(A) derived small RNAs
[mivaRNAI(A)] generated active RISC (Figure 3C, lanes
3 and 4). In contrast, only the 30-strand of VA RNAI(G)
derived small RNAs [mivaRNAI(G)] generated active
RISC complexes (Figure 3, lanes 5 and 6). These results
are in perfect agreement with the data obtained from
infections using viruses expected to produce both VA
RNAI species or VA RNAI(G) only (Table 1). Taken
together our data demonstrate that mivaRNAI(A)
generates small RNAs from both strands of the terminal
stem that are incorporated into RISC whereas
mivaRNAI(G) generates active RISC complexes only
from the 30-strand of the terminal stem.
Mapping the Dicer processing site in VA RNAI(A)
and VA RNAI(G)
Since the RNAi eﬀector complex will cleave a target RNA
between nucleotide 10 and 11 relative to the 50-end of the
guiding siRNA, the exact cleavage position in a target
RNA will help to ﬁne map the 50-end of both strands of
the mivaRNAs produced in transfected or adenovirus-
infected cells. As control RNAs, we used annealed syn-
thetic siRNAs designed to mimic the predicted ‘G’ start
and ‘A’ start mivaRNAI (Figure 4A mivaRNAI(A) and
mivaRNAI(G)). Although these siRNAs were
unphosphorylated they are expected to become rapidly
phosphorylated at the 50-end by the human RNA kinase
hClp1 (26). Using this strategy, we could ﬁne map the start
nucleotide of both the 50- and 30-strands of mivaRNAI(A)
and mivaRNAI(G). As shown in Figure 4B, strand
loading was highly asymmetric, and opposite, for the
two synthetic short RNA duplexes with the 50-strand of
mivaRNAI(A) and the 30-strand of mivaRNAI(G) being
preferentially assembled into RISC. In part, this variation
in strand loading eﬃciency between the two siRNAs may
result from diﬀerences in the thermodynamic stability of
the short RNA ends. As expected, the synthetic
mivaRNAI(A) generated a 50-strand cleavage product
that was detectable longer (three nucleotides) than
the cleavage product produced from the synthetic
mivaRNAI(G) (compare Figure 4B, lanes 2 and 3).
Importantly, in Ad5 infected cells and in cells transfected
with plasmid pVA RNAI(A) the 50-strand cleavage
product was identical in size to the synthetic
Figure 3. VA RNAI (A), but not VA RNAI (G), generates active RISC containing the 50-strand of mivaRNAI. (A) Schematic representation of the
terminal sequence of VA RNAI and the oligonucleotide used for primer extension. (B) Primer extension on total RNAs prepared from control
293-Ago2 cells (lane 1) or cells transfected with plasmid pVA RNAI(A) (lane 2) or pVA RNAI(G) (lane 3) or infected with virus Ad5 (lane 4) or
wt900 infected cells (lane 5), were analyzed by primer extension for the transcription initiation start sites of VA RNAI. The products generated from
‘A’ start and ‘G’ start VA RNAI are indicated in the Figure. (C) The 293-Ago2 cells were transfected with plasmids pVA RNAI(A), pVA RNAI(G)
or the empty vector as a control. The immunopuriﬁed RISC complexes from S15 cytoplasmic extracts were assayed for activity against the reverse
VAI 50 or VAI 30 target RNAs.
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50-strand of mivaRNAI(A) was not processed.
Since mivaRNAI(A) initiates transcription 3 nucleo-
tides upstream of VA RNAI(G) the predicted start
position of the 30-strand would be expected to be shifted
down three nucleotides on the terminal stem compared
to mivaRNAI(G) (Figure 4A). As shown in Figure 4B,
the synthetic siRNAs reproduced the expected result
with mivaRNAI(A) generating a 3 nucleotide shorter
30-strand cleavage product compared to mivaRNAI(G)
(lanes 2 and 3). Importantly the 30-strand cleavage site
was identical in pVA RNAI(A), pVA RNAI(G) trans-
fected cells and Ad5-infected cells suggesting that Dicer
processing of VA RNAI(A) and VA RNAI(G) occurs at
the same position in the terminal stem (Figure 4A). As a
consequence the mivaRNAI(A) 50-strand is expected to be
three nucleotides longer than the corresponding 50-strand
from mivaRNAI(G). Also, the 30-strand in both
mivaRNAs produced in Ad5-infected cells will be identical
(Figure 4A). To conﬁrm this, another synthetic short
RNA duplex mivaRNAI(A*) (Figure 4A), which was
designed to mimic the actual mivaRNAI(A) produced in
infected cells, was tested for its ability to guide RISC to
cleave the target RNA. As shown in Figure 4B, the
mivaRNAI(A*) 30- and 50-strand cleavage sites were the
same as in those produced in pVA RNAI(A), pVA
RNAI(G) transfected cells and Ad5-infected cells, con-
ﬁrming our hypothesis.
The 50-end phosphorylation status diﬀers between
mivaRNAs generated from VA RNAI(A) and VA RNAI(G)
Since the VA RNAs are transcribed by RNA polymerase
III, a large proportion of both VA RNAI(A) and VA
RNAI(G) would be expected to have a tri-phosphorylated
50-end. A direct measurement of the phosphorylated status
of the 50-end of VA RNAI showed that only about 50% of
VA RNAI carries a tri-phosphate end. The rest of the
population has di-phosphate (40%) or mono-phosphate
(10%) ends (17). Functional siRNAs and miRNAs
have a 50-mono-phosphate that is generated by Dicer
cleavage (27,28). Commercial siRNAs are usually
unphosphorylated but become rapidly phosphorylated
after transfection (26).
To test whether the 50-strand of mivaRNAI produced in
plasmid pVA RNAI(G) and pVA RNAI(A) transfected
cells had a 50-mono-phosphate or a 50 multiple phosphate
group, we used a combination of enzymes to treat the
small RNA pool prepared from immuno-puriﬁed RISC
complexes. The RNA samples were treated with calf intes-
tinal alkaline phosphatase (CIAP) that removes all types
of 50-phosphates, T4 polynucleotide kinase (PNK), which
adds a monophosphate to a free 50-end and Terminator
50-exonuclease (TE), which only degrades RNAs con-
taining a 50-mono-phosphate. After enzyme treatment,
the 50-o r3 0-strands of mivaRNAI were analyzed by
northern blotting.
As shown in Figure 5A, the 50-strand northern blot
analysis showed one predominant band in pVA RNAI(A)
transfected cells (lane 1). This band was sensitive to TE
treatment (lane 2), suggesting that it had a mono-
phosphate at its 50-end. A small fraction of the RNA
was TE resistant and could represent mivaRNAI(A)
species that had tri-phosphorylated 50-ends. Much to
our surprise, we could also detect the 50-strand of
mivaRNAI(G) in immuno-puriﬁed RISC complexes
(Figure 5A, lane 6). This was unexpected since the
50-strand of VA RNAI(G) does not generate active RISC
complexes (Figure 3C, lane 5; Figure 4B, lane 7). This
species was resistant to TE treatment showing that it did
not have a 50-mono-phosphate. CIAP treatment of the
Figure 4. Mapping the Dicer processing site in VA RNAI(A) and VA
RNAI(G). (A) Schematic drawing showing the diﬀerence in nucleotide
sequence at the terminal stems of VA RNAI(A) and VA RNAI(G).
The synthetic short double-stranded RNAs (shown in bold letters) were
designed to mimic the predicted ‘A’ start and ‘G’ start mivaRNAI.
Note that the structure of the extra base pairs at the beginning of
the stem in the VA RNAI(A) structure were predicted. (B) S15
cytoplasmic extracts prepared from uninfected 293-Ago2 cells (Mock,
lanes 1–4) or cells infected with wild-type Ad5 (lane 5) or cells
transfected with plasmids pVA RNAI(A) (lane 6) or pVA RNAI(G)
(lane 7) were assayed for RISC activity against the reverse VAI 50
(upper panel) or reverse VAI 30 (lower panel) target RNAs. The
uninfected cytoplasmic extracts were mixed with water (lane 1), 2
pmol synthetic ‘G’ start mivaRNAI (lane 2), 2 pmol short version
(lane 3) or the experimentally veriﬁed version of the ‘A’ start
mivaRNAI (lane 4). The cleavage products from diﬀerent
mivaRNAIs are indicated by arrows.
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forbothVARNAI(A)andVARNAI(G)(Figure5A,lanes
3 and 8). This result was expected since the method we use
to cross-link the RNA to the membrane requires a phos-
phategroupontheRNA(23).Asexpected,PNKtreatment
restores a 50-mono-phosphate to the CIAP treated small
RNAs from pVA RNAI(A) and pVA RNAI(G)
transfected cells (Figure 5A, lanes 4 and 9), a phosphate
that makes the RNAs susceptible to degradation by TE
treatment (Figure 5A, lanes 5 and 10). Collectively, these
results show that mivaRNAI(A) generates active 50-strand
RISC complexes that contain small RNAs with a 50-end
mono-phosphate, whereas mivaRNAI(G) generates a low
frequency of inactive 50-strand RISC complexes that
contain small RNAs that do not have a 50-mono-
phosphate. Potentially, they may have multiple phosphate
groups at their 50-end.
The same analysis of 30-strand incorporation in pVA
RNAI(A) and pVA RNAI(G) transfected cells
demonstrated that only one type of small RNA was incor-
porated into RISC (Figure 5B). Compared to the 50-strand
these small RNAs were very eﬃciently incorporated into
RISC and sensitive to TE treatment indicating that they
have a mono-phosphate at their 50-end and therefore,
most likely, are the products of Dicer cleavage. Note
that the alkaline phosphatase treatment was not 100%
eﬀective in this experiment (Figure 5, lanes 3 and 8).
The 30-strand of mivaRNAI is eﬃciently
incorporated into RISC
To measure the relative amounts of the 50- and 30-strands
of mivaRNAI in RISC puriﬁed from Ad5 infected
293-Ago2 cells we quantitated the abundance of respective
strand by northern blot analysis. As a standard we used
ﬁxed amounts of the two strands of a chemically
synthesized mivaRNAI (Figure 6, lanes 2–6). After
transfer, the ﬁlters were hybridized with 50-end labeled
DNA oligonucleotides complementary to the 50-o r
30-strands of mivaRNAI. As shown in Figure 6, the
physical amount of the 30-strand of mivaRNAI is dramat-
ically higher compared to the 50-strand. Quantiﬁcation of
this type of gels showed that the 30-strand is in >200-fold
excess compared to the 50-strand. This result was surpris-
ing since functional RISC with the 30-strand in Ad5
infected cells was only around 4-fold higher compared to
the 50-strand (Figure 2, lanes 3 and 4). Taken together, our
results show that the 30-strand of mivaRNAI is the pre-
ferred substrate for RISC assembly. However, these RISC
complexes appear to have a very low speciﬁc activity, only
around 2% compared to the RISC complexes assembled
on the 50-strand.
The 50-strand of mivaRNAI(A) generates more stable
RISC complexes compared to the 30-strand
To determine the stability of the RISC complexes formed
with the 50- and 30-strands of mivaRNAI we pre-incubated
S15 cytoplasmic extracts from Ad5 infected 293 cells
with a constant amount of a non-speciﬁc competitor
siRNA for 0, 10, 30, 60 or 120min. The pre-incubation
was terminated by quick-freezing the extract in liquid
nitrogen. As shown in Figure 7A, the activity of the
30-strand RISC decreased more rapidly than that of the
50-strand. Thus, whereas the 50-strand RISC complexes
remained essentially unaﬀected during the 2h pre-
incubation period the 30-strand RISC complexes were
reduced to <40% of the control. Taken together, these
results suggest that the active RISC complexes formed
with the 50-strand of mivaRNAI are signiﬁcantly more
stable than the corresponding complexes formed with
the 30-strand.
Cellular miRNAs are believed to form stable RISC
complexes (32, 33). To determine whether the 30-strand
Figure 5. The phosphorylation status of mivaRNAIs derived from VA
RNAI(A) and VA RNAI(G). The RISC associated RNAs from pVA
RNAI(A) or pVA RNAI(G) transfected cells were treated with
combinations of calf intestinal alkaline phosphatase (CIAP), T4
polynucleotide kinase (PNK) and Terminator 50-exonuclease (TE).
After enzyme treatment, the 50-( A)o r3 0-strands (B) of mivaRNAI
were analyzed by northern blotting.
Figure 6. The 30-strand of mivaRNAI is eﬃciently incorporated into
RISC. The RISC associated RNAs from wild-type Ad5 infected cells
were analyzed for the abundance of 30-strand (A) and 50-strand (B)o f
mivaRNA I by northern blotting. Diﬀerent amounts (from 0.05 to
5pmol) of chemically synthetic mivaRNAI were phosphorylated and
used as standards for quantiﬁcation.
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stability of RISC complexes assembled on three cellular
miRNAs: miR-18a, miR-93 and miR-106b. We selected
these miRNAs because they belong to diﬀerent miRNA
clusters and have been annotated in diﬀerent databases as
expressed in 293 cells. As shown in Figure 7B, all three
miRNAs were essentially unaﬀected by the 2h pre-
incubation conﬁrming that cellular miRNAs form stable
RISC complexes. This result also demonstrates that the
50-strand mivaRNAI(A) generates RISC complexes with
a stability similar to cellular miRNAs, whereas the
30-strand form highly unstable complexes.
DISCUSSION
In our previous work, we showed that small RNAs
generated from both strands of the terminal stem of VA
RNAI were incorporated into functional RISC during a
dl703 infection (4). This result is not controversial since it
has been observed by other groups as well (5,7). However,
in a follow-up study we noted that in cells infected with
the wt900 virus, only the 30-strands of VA RNAI were
loaded into active RISC (8). This result was at ﬁrst sight
confusing.
Here, we have analyzed the basis for this diﬀerence
in RISC activity. Our results show that the decisive
parameter determining strand incorporation results from
which VA RNAI species is expressed during the infection.
Thus, VA RNAI comes in two variants, VA RNAI(G)
and VA RNAI(A). These two species diﬀer from each
other in that VA RNAI(A) initiates transcription 3
nucleotides upstream of VA RNAI(G) (Figure 1C). In
Ad5-infected cells, both strands of the terminal stem of
VA RNAI(G) and VA RNAI(A) were assembled into
RISC, albeit with diﬀerent eﬃciencies and consequences
for RISC activity. The 30-strand processed from both VA
RNAI(A) and VA RNAI(G) are identical in sequence
(Figure 4A), and also the preferred strand used in RISC
assembly (Figure 5), exceeding the 50-strand by >200-fold
in a lytic Ad5-infected cell (Figure 6). It should be noted
that although the VA RNAI(A) 50-strand is three
nucleotides longer than the corresponding strand from
VA RNAI(G) Dicer is expected to cleave the terminal
stem of both VA RNAs at the same position since Dicer
measures the distance to cleavage site based on the 30-end
of the dsRNA (29,30). Also, it is noteworthy that the
50-strand of both mivaRNAI(A) and mivaRNAI(G)
were assembled into RISC although our analysis showed
that the 50-strand of mivaRNAI(A) was assembled more
eﬀectively (Figure 5A, lanes 1 and 6) and generated RISC
complexes that were functional in cleaving a target RNA
in vitro (Figure 3C, lanes 3 and 4). The 50-strand
of mivaRNAI(G) is functionally inactive and contains a
50-end that does not have a mono-phosphate, whereas the
active 50-strand of mivaRNAI(A) has a mono-phosphate
(Figure 5).
Although the 30-strand of mivaRNAI was assembled
into RISC with a >200-fold preference compared to the
50-strand (Figure 6) it generated unstable RISC complexes
(Figure 7) with a surprisingly low cleavage activity, only
around 2% of that of the 50-strand. This result could mean
that VA RNAI, with the exception of the 50-strand of
mivaRNAI(A), generates small RNAs that functionally
inactivate RISC, thereby potentially contributing to the
suppressive eﬀect of the VA RNAs on RNAi (4–7).
Such a mechanism would be attractive since it resembles
the way VA RNAI binds and sequesters PKR. Thus, VA
RNAI may have dual function during virus replication.
It may antagonize the cellular defense pathways against
both long dsRNA by binding and sequestrating PKR and
short dsRNA by saturating RISC with mivaRNAs that do
not generate enzymatically active complexes. Although
this model is attractive, we can not exclude the possibility
that the 30-strand of mivaRNAI is a highly eﬃcient viral
miRNA that in the extract we prepare already is occupied
by binding to cellular mRNAs. Since our assay system
relies on the cleavage of an added reporter transcript
such engaged RISC complexes will be scored as inactive
in our RISC experiments. In addition, it is possible
that structural constrains limit target accessibility for the
50- and 30-strand mivaRNAs. Also, the lower stability of
the RISC complexes formed with the 30-strand (Figure 7)
contributes to the lower activity in the RISC assays.
A high priority in our future work will be to clarify this
point.
Curiously VA RNAI(A) appears to produce a
50 mivaRNAI carrying a mono-phosphate instead of the
Figure 7. RISC complexes formed on the 50-strand of mivaRNAI are
more stable than RISC assembled on the 30-strand. (A) S15 cytoplasmic
extracts prepared from Ad5 infected 293 cells were pre-incubated with
10mM of a non-speciﬁc siRNA for 0, 10, 30, 60 or 120min before
RISC activity directed against the reverse VAI 50 or reverse VAI 30
target RNAs was measured. The cleavage ratio of target RNAs was
quantitated by PhosphorImager scanning. The cleavage activity of the
zero minute sample was arbitrarily set as 100%. (B) Target RNAs
complementary to miR-18a, miR-93 and miR-106b were incubated in
S15 extracts prepared from 293 cells as described in (A). RISC activity
was quantitated by PhosphorImager scanning and the cleavage activity
of the zero minute sample set as 100%.
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The RISC cleavage mapping experiment (Figure 4B)
suggests that the 50-end of this small RNA is not generated
by RNA processing. More likely, the 50-strand of
mivaRNAI(A) is susceptible to dephosphorylation. Note
that, 50% of the total pool of VA RNAI has mono- or
di-phosphorylated 50-termini in vivo (17). In fact, a closer
inspection of this article indicates that a larger fraction of
the VA RNAI(A) species has lost 50 phosphates compared
to VA RNAI(G) (see Figure 2 in ref. 17).
There are numerous studies that emphasize that the
sequence and the structural features of the siRNA
duplex are important and critical determinants for
strand selection and RISC loading (27,31). The thermo-
dynamic stability at the ends of the siRNA duplex appears
to be important for RISC loading. Thus, experiments in
Drosophila embryonic extracts have shown that the strand
that is more loosely paired at its 50-end is selectively
assembled into RISC (32,33). However, in mammals
there is no deﬁnite correlation between siRNA thermo-
dynamic stability and strand selection (34). It seems
more probable that the selection may be mediated by a
combination of thermodynamic stability and a, yet to be
described, structural feature component of the dsRNA.
The predicted thermodynamic stability of the 50-end of
the 30-strand is signiﬁcantly lower compared to the
50-ends of the 50-strands in both mivaRNAI(G) and
mivaRNAI(A) (Figure 4A). Thus, it seems reasonable
that this diﬀerence in strand stability explains the highly
asymmetric overrepresentation of the 30-strand in RISC.
Furthermore, this work suggests that RISC stability could
be an important parameter to control RISC functionality.
Thus, the 30-strand of mivaRNAI assembled eﬃciently
into RISC but generated unstable complexes (Figure 7).
We do not know whether this represents a general mech-
anism regulating small RNA function in mammalian cells
or if it is a virus-speciﬁc mechanism. However, it does not
seem unreasonable to predict that future work will show
that the functionality of both cellular and viral small RNA
complexes will be regulated at the level of stability.
An important aspect of our work that we have not yet
addressed is that the virus mutant defective in VA
RNAI(A) production grows equally well as wild-type
Ad5 in Hela cells (data not shown). This suggests that
the production of the 50 mivaRNA from VA RNAI(A)
is not essential for virus growth at least not in tissue
culture cells (16). Both VA RNAI(A) and VA RNAI(G)
are made during the early and late phase of viral life cycle,
but the proportion of ‘A’ start VA RNAI appears to
increase late (17). It is possible that VA RNAI(A) and
VA RNAI(G) have distinct roles in the RNAi/miRNA
pathways, a function that may be important for
adenovirus growth in nature. Previous work has suggested
that mivaRNAs can function as miRNAs and regulate
translation of cellular mRNAs (7,8). Therefore, RISC
loading of the 50-strand of mivaRNAI(A), in addition to
the 3-strand, will yield additional potential target genes
that might be regulated by the mivaRNAs (see
Supplementary Material for potential target mRNAs). It
is possible that such targets may contribute to the
establishment of a benign long-term infection, or be
related to tissue-speciﬁc acute infections.
Recombinant adenovirus vector systems have become
widely used in gene therapy and gene transfer applications
(35). However, adenovirus vectors designed to express
short-hairpin RNAs (shRNAs) may suﬀer from negative
eﬀects caused by expression of large amounts of com-
peting mivaRNAs. The basic function of VA RNAI
during an adenovirus infection is to inhibit PKR (10)
and this function is not dispensable for high-titer virus
growth (21). Uncovering the exact mechanism involved
in VA RNAI terminal stem processing and strand selec-
tion together with the ﬁne-mapping of the mivaRNAIs
expressed in Ad5-infected cells might be helpful in the
design of a viral vector that retains the wild type PKR
inhibitory activity but lacks competing mivaRNA expres-
sion. For example, based on the fact that so far it seems
that strand selection is based on thermodynamic stability
of the produced 50-ends, it should be possible to increase
the strength of the 30-strand hybridization by changing
the two A–T base pairs (50-AGAC) to G–C base pairs
(50-GGGC) in the terminal stem. In combination with
the 2bp deletion restricting VA RNAI(A) synthesis such
a VA RNAI gene would retain its PKR inhibitory activity
and produce a Dicer cleavage product were both strands
would have diﬃculties to enter RISC eﬃciently.
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